Evaluation of the Single-Use Pre-Filled Autoinjector (BCB119)

NCT02349802 Phase 1 COMPLETED

Phase I study to determine the device-related injection failure rate of the single-use, pre-filled autoinjector.

Details

Lead sponsor	AstraZeneca
Phase	Phase 1
Status	COMPLETED
Enrolment	3052
Start date	2013-02
Completion	2013-12

Conditions

• Healthy Subjects

Interventions

• Auto-injector with exenatide suspension
• Syringe with exenatide suspension

Primary outcomes

• Number of device-related failure injections — 10 week study
  The primary outcome measure is the number of device-related injection failures of the single-use, pre-filled auto-injector.

Countries

United States